AQR Capital Management LLC Sells 2,610,389 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

AQR Capital Management LLC lowered its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 99.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,079 shares of the biotechnology company’s stock after selling 2,610,389 shares during the quarter. AQR Capital Management LLC owned approximately 0.31% of Atara Biotherapeutics worth $128,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Atara Biotherapeutics during the 2nd quarter valued at approximately $53,000. Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. Redmile Group LLC raised its holdings in Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after purchasing an additional 156,863 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after purchasing an additional 4,903,159 shares during the last quarter. Finally, Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Up 0.3 %

NASDAQ:ATRA opened at $9.41 on Friday. The company has a fifty day moving average of $7.88 and a 200-day moving average of $11.39. The firm has a market capitalization of $45.33 million, a P/E ratio of -0.18 and a beta of 0.50. Atara Biotherapeutics, Inc. has a twelve month low of $4.96 and a twelve month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($3.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to analyst estimates of $48.30 million. On average, analysts anticipate that Atara Biotherapeutics, Inc. will post -12.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ATRA. Canaccord Genuity Group restated a “buy” rating and set a $13.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, August 13th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their price target for the stock from $25.00 to $18.00 in a report on Friday, August 16th. StockNews.com started coverage on shares of Atara Biotherapeutics in a report on Wednesday, June 26th. They set a “hold” rating for the company. The Goldman Sachs Group lowered their price objective on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $14.00.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.